FAB — Fusion Antibodies Share News
0.000.00%
Last trade - 00:00- £7.57m
- £6.86m
- £2.11m
Fusion Antibodies - Grant of options and issue of shares to directors
Fusion Antibodies - Placing to raise £1,375,000
Fusion Antibodies - Follow-on project award and R&D update
Brief: Fusion Antibodies Gets R&D Tax Credit From HMRC For FY23
Fusion Antibodies - Director/PDMR Shareholding
Brief: Fusion Antibodies H1 Pretax Profit GBP -1.42 Mln
Brief: Fusion Antibodies Says Revenues For FY2024 Expected To Be Significantly Weighted Towards H2
Fusion Antibodies - Half-year Report
Brief: Fusion Antibodies Signs Collaboration Deal With National Cancer Institute For Use Of Optimal
Fusion Antibodies - OptiMAL collaboration agreement
Brief: Fusion Antibodies Anticipates Revenues For FY2024 To Be Significantly Weighted Towards Second Half Of Financial Year
Fusion Antibodies - Half year trading update
Brief: Fusion Antibodies Says FY Revenue Down 40% To 2.9 Mln Stg
Fusion Antibodies - Final Results
Brief: Fusion Antibodies Receives First Purchase Order For Its AI/Ml-AB(TM) Services
Brief: Fusion Antibodies Says Stephen Smyth Appointed As Interim CFO Of Co
Brief: Fusion Antibodies Provides Update On AI/Ml-AB™ Antibody Discovery Service
Fusion Antibodies - Update on AI/ML-Ab™ antibody discovery service
Brief: Fusion Antibodies Completes Restructuring Process To Reduce Annualised Costs By About £2.2 Mln